Incremental Healthcare Costs of Diabetes Mellitus in a Middle-Income Country Using Administrative Healthcare Data

IF 1.4 Q3 HEALTH CARE SCIENCES & SERVICES Value in health regional issues Pub Date : 2024-05-06 DOI:10.1016/j.vhri.2024.100992
Santiago Castro-Villarreal MSc , Sara Miksi MSc , Adriana Beltrán-Ostos MD, MSc , Carlos F. Valencia MSc, PhD
{"title":"Incremental Healthcare Costs of Diabetes Mellitus in a Middle-Income Country Using Administrative Healthcare Data","authors":"Santiago Castro-Villarreal MSc ,&nbsp;Sara Miksi MSc ,&nbsp;Adriana Beltrán-Ostos MD, MSc ,&nbsp;Carlos F. Valencia MSc, PhD","doi":"10.1016/j.vhri.2024.100992","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>To estimate the incremental medical cost of diabetes mellitus using information from administrative databases in Colombia.</p></div><div><h3>Methods</h3><p>We carried out a retrospective cohort study with administrative health databases from Colombian population affiliated in the contributory health insurance scheme. We used an operative definition to select the cohort with diabetes. Incremental cost and cost ratio of diabetes were estimated using an inverse probability weighting of treatment approach to find the causal effect of having the disease. Weights were calculated by a propensity score method using a Random Forest model. The flexibility of this machine learning algorithm allows to have a better specification and bias reduction. Additionally, we reported incremental costs and cost ratios with confidence intervals using bootstrapping and analyzed costs by age groups and complications associated with diabetes.</p></div><div><h3>Results</h3><p>The estimated prevalence of diabetes was 2834 per 100 000 cases, in 2018. The group with diabetes was comprised 634 015 people and the control group 1 524 808. The calculated annual direct medical cost was $860, for which the incremental cost was $493 and the cost ratio 2.34. The incremental annual cost for some type of complication ranges from $1239 to $2043, renal complication being the most expensive. Incremental cost by age groups ranges from $347 to $878, being higher in younger people.</p></div><div><h3>Conclusions</h3><p>Although the cost of diabetes in Colombia ranges among the global averages and is similar to other Latin-American countries, a greater incremental cost was found in patients with renal, circulatory, and neurologic complications.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212109924000256/pdfft?md5=0f1b0c4f6ecc7851bc484bc6dd03faa6&pid=1-s2.0-S2212109924000256-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Value in health regional issues","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212109924000256","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

To estimate the incremental medical cost of diabetes mellitus using information from administrative databases in Colombia.

Methods

We carried out a retrospective cohort study with administrative health databases from Colombian population affiliated in the contributory health insurance scheme. We used an operative definition to select the cohort with diabetes. Incremental cost and cost ratio of diabetes were estimated using an inverse probability weighting of treatment approach to find the causal effect of having the disease. Weights were calculated by a propensity score method using a Random Forest model. The flexibility of this machine learning algorithm allows to have a better specification and bias reduction. Additionally, we reported incremental costs and cost ratios with confidence intervals using bootstrapping and analyzed costs by age groups and complications associated with diabetes.

Results

The estimated prevalence of diabetes was 2834 per 100 000 cases, in 2018. The group with diabetes was comprised 634 015 people and the control group 1 524 808. The calculated annual direct medical cost was $860, for which the incremental cost was $493 and the cost ratio 2.34. The incremental annual cost for some type of complication ranges from $1239 to $2043, renal complication being the most expensive. Incremental cost by age groups ranges from $347 to $878, being higher in younger people.

Conclusions

Although the cost of diabetes in Colombia ranges among the global averages and is similar to other Latin-American countries, a greater incremental cost was found in patients with renal, circulatory, and neurologic complications.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
利用行政医疗保健数据计算中等收入国家糖尿病的增量医疗保健成本
目的利用哥伦比亚行政数据库中的信息估算糖尿病的增量医疗成本。方法我们利用行政健康数据库对参加缴费健康保险计划的哥伦比亚人口进行了一项回顾性队列研究。我们使用手术定义来选择糖尿病患者。我们采用反概率加权治疗法估算了糖尿病的增量成本和成本比,以找出患病的因果效应。权重是通过使用随机森林模型的倾向得分法计算得出的。这种机器学习算法具有灵活性,可以更好地规范和减少偏差。此外,我们还利用引导法报告了增量成本和成本比率及置信区间,并按年龄组和糖尿病相关并发症分析了成本。糖尿病患者组有 634 015 人,对照组有 1 524 808 人。计算得出的年度直接医疗成本为 860 美元,其中增量成本为 493 美元,成本比为 2.34。某种并发症的年增量成本从 1239 美元到 2043 美元不等,其中肾脏并发症的成本最高。结论虽然哥伦比亚的糖尿病费用处于全球平均水平,与其他拉美国家相似,但肾脏、循环系统和神经系统并发症患者的增量成本更高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Value in health regional issues
Value in health regional issues Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
CiteScore
2.60
自引率
5.00%
发文量
127
期刊最新文献
Understanding What Matters: Stakeholder Views on Decision Criteria for Cancer Drug Selection in the Public Sector in Malaysia. Postpartum Screening for Type 2 Diabetes in Women With a History of Gestational Diabetes Mellitus: A Cost-Effectiveness Analysis in Singapore Cost-Utility Analysis of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy Regimen in Comparison With Gemcitabine and Cisplatin Chemotherapy Regimen in the Treatment of Patients With Muscle Invasive Bladder Cancer in Iran. Editorial Board Table of Contents
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1